REG-Bioventix Plc: Result of AGM

BioventixAnnouncement

09/12/2021 15:45

Bioventix plc
(“Bioventix” or the “Company”)

Result of AGM

Bioventix plc (AIM: BVXP) announces that at its Annual General Meeting
(“AGM”), all resolutions put to shareholders were duly passed.
 

For further information please contact:

 Bioventix plc Peter Harrison Bruce Hiscock     Chief Executive Officer Chief Financial Officer  Tel: 01252 728 001  
 finnCap Ltd Geoff Nash/Simon Hicks Alice Lane  Corporate Finance ECM                            Tel: 020 7220 0500  

 

About Bioventix plc:

Bioventix (www.bioventix.com) specialises in the development and commercial
supply of high-affinity monoclonal antibodies with a primary focus on their
application in clinical diagnostics, such as in automated immunoassays used in
blood testing. The antibodies created at Bioventix are generated in sheep and
are of particular benefit where the target is present at low concentration and
where conventional monoclonal or polyclonal antibodies have failed to produce
a suitable reagent. Bioventix currently offers a portfolio of antibodies to
customers for both commercial use and R&D purposes, for the diagnosis or
monitoring of a broad range of conditions, including heart disease, cancer,
fertility, thyroid function and drug abuse. Bioventix currently supplies
antibody products and services to the majority of multinational clinical
diagnostics companies. Bioventix is based in Farnham, UK and its shares are
traded on AIM under the symbol BVXP.



Copyright (c) 2021 PR Newswire Association,LLC. All Rights Reserved